Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 15/20 | 0.40 |
| ▸ | PMAIP1 | Q13794 | 6/20 | 0.39 |
| ▸ | BAD | Q92934 | 7/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25786233 | 0.94 | BAD (0.37) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786224 | 0.93 | BAD (0.43) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786617 | 0.88 | BAD (0.45) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786229 | 0.88 | BAD (0.42) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25793459 | 0.87 | BAD (0.35) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25294232 | 0.87 | MCL1 (0.34) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL29897053 | 0.87 | MCL1 (0.34) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786253 | 0.86 | BAD (0.40) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786248 | 0.85 | BAD (0.41) | MCL1PMAIP1BADBCL2BCL2L1 | |
| SCHEMBL25786228 | 0.85 | BAD (0.38) | MCL1PMAIP1BADBCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | MCL1 1/4885PMAIP1 807/4885BAD 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.